Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study - ScienceDirect
Vorapaxar - Wikipedia
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology
TRA 2°P-TIMI 50 – TIMI STUDY GROUP
A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivity™) | SpringerLink
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial - The Lancet
Vorapaxar sulfate (SCH 530348 sulfate) | PAR-1 Antagonist | MedChemExpress
Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients? | tctmd.com
Vorapaxar - wikidoc
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events – A Review on Vorapaxar - ScienceDirect
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
Drug Trials Snapshot: Zontivity (vorapaxar) | FDA
![PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c4d402004bb1cd7f7142aa35447751937911b5ff/2-Figure1-1.png "PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar")
PDF] Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis | Semantic Scholar
Zontivity (vorapaxar) for the Reduction of Thrombotic Cardiovascular Events - Clinical Trials Arena
Vorapaxar | Uses, Brand Names, Mechanism Of Action
IJMS | Free Full-Text | Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Drug Trials Snapshot: Zontivity (vorapaxar) | FDA
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside - Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo, 2018
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology
Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease - Justin T. Morrison, Nicholas Govsyeyev, Connie N. Hess, Marc P. Bonaca, 2022
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
![Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC](https://www.trc-canada.com/prod-img/V758202.png "Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC")
Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
Vorapaxar in the Secondary Prevention of Atherothrombotic Events | NEJM
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction | tctmd.com
Vorapaxar, a Platelet Thrombin Receptor Antagonist, in Acute Coronary Syndromes Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees. - ppt download
